Screener
Bristol-Myers Squibb BMY Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on the most recent quarter.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's net debt / EBITDA?
- Bristol-Myers Squibb (BMY) reported net debt / EBITDA of 2.3× in Q2 2026.
- How has Bristol-Myers Squibb's net debt / EBITDA changed year-over-year?
- Bristol-Myers Squibb's net debt / EBITDA decreased by 19.5% year-over-year, from 2.8× to 2.3×.
- What is the long-term trend for Bristol-Myers Squibb's net debt / EBITDA?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's net debt / EBITDA has grown at a -23.4% compound annual growth rate (CAGR), from 10.5× to 2.8×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Bristol-Myers Squibb's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude